Minerva Neurosciences (NERV) Competitors $1.70 -0.03 (-1.73%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NERV vs. BLUE, PRLD, APLT, OSTX, PEPG, ATNM, ATRA, XCUR, ADVM, and ALGSShould you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include bluebird bio (BLUE), Prelude Therapeutics (PRLD), Applied Therapeutics (APLT), OS Therapies (OSTX), PepGen (PEPG), Actinium Pharmaceuticals (ATNM), Atara Biotherapeutics (ATRA), Exicure (XCUR), Adverum Biotechnologies (ADVM), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry. Minerva Neurosciences vs. Its Competitors bluebird bio Prelude Therapeutics Applied Therapeutics OS Therapies PepGen Actinium Pharmaceuticals Atara Biotherapeutics Exicure Adverum Biotechnologies Aligos Therapeutics Minerva Neurosciences (NASDAQ:NERV) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations. Which has more volatility & risk, NERV or BLUE? Minerva Neurosciences has a beta of -0.34, indicating that its stock price is 134% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Which has stronger earnings and valuation, NERV or BLUE? Minerva Neurosciences has higher earnings, but lower revenue than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A$1.44M$0.822.07bluebird bio$103.95M0.47-$211.91M-$41.32-0.12 Does the media prefer NERV or BLUE? In the previous week, bluebird bio had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 2 mentions for bluebird bio and 0 mentions for Minerva Neurosciences. bluebird bio's average media sentiment score of 0.31 beat Minerva Neurosciences' score of 0.00 indicating that bluebird bio is being referred to more favorably in the news media. Company Overall Sentiment Minerva Neurosciences Neutral bluebird bio Neutral Do insiders & institutionals have more ownership in NERV or BLUE? 34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 87.4% of bluebird bio shares are held by institutional investors. 8.6% of Minerva Neurosciences shares are held by insiders. Comparatively, 1.4% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is NERV or BLUE more profitable? Minerva Neurosciences has a net margin of 0.00% compared to bluebird bio's net margin of -565.74%. Minerva Neurosciences' return on equity of -20.68% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A -20.68% 15.73% bluebird bio -565.74%-322.46%-53.17% Do analysts prefer NERV or BLUE? Minerva Neurosciences presently has a consensus price target of $5.00, suggesting a potential upside of 194.12%. bluebird bio has a consensus price target of $44.60, suggesting a potential upside of 797.38%. Given bluebird bio's stronger consensus rating and higher probable upside, analysts clearly believe bluebird bio is more favorable than Minerva Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00bluebird bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Summarybluebird bio beats Minerva Neurosciences on 8 of the 15 factors compared between the two stocks. Get Minerva Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NERV vs. The Competition Export to ExcelMetricMinerva NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.10M$2.44B$5.53B$8.95BDividend YieldN/A1.77%5.38%4.08%P/E Ratio2.078.8627.4020.24Price / SalesN/A678.05419.60118.25Price / Cash8.28157.0736.6357.47Price / Book-0.464.638.085.67Net Income$1.44M$31.34M$3.16B$248.47M7 Day Performance-4.49%3.25%2.84%3.32%1 Month Performance-8.11%6.80%3.69%5.20%1 Year Performance-45.86%1.89%35.30%21.35% Minerva Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NERVMinerva Neurosciences3.19 of 5 stars$1.70-1.7%$5.00+194.1%-45.9%$12.10MN/A2.079Gap DownBLUEbluebird bio2.1245 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520News CoveragePRLDPrelude Therapeutics3.4506 of 5 stars$0.84-2.4%$4.50+435.7%-77.6%$48.58M$7M-0.50120APLTApplied Therapeutics3.8192 of 5 stars$0.30-12.5%$6.10+1,933.3%-92.3%$48.55M$460K-0.7030Gap UpOSTXOS Therapies2.701 of 5 stars$1.70-4.5%$18.00+958.8%N/A$47.77MN/A-1.98N/ANews CoverageGap UpPEPGPepGen2.9446 of 5 stars$1.39-4.1%$7.67+451.6%-92.7%$47.44MN/A-0.4430Trending NewsATNMActinium Pharmaceuticals2.4989 of 5 stars$1.52+1.3%$4.00+163.2%N/A$47.42M$81K-1.0930ATRAAtara Biotherapeutics4.1269 of 5 stars$7.88-0.8%$17.75+125.3%+3.9%$47.33M$128.94M-2.12330XCURExicure1.9935 of 5 stars$6.50-13.0%N/A+1,941.3%$47.19M$500K-1.3550Earnings ReportADVMAdverum Biotechnologies4.2542 of 5 stars$2.23-0.9%$26.40+1,083.9%-66.5%$47M$1M-0.35190ALGSAligos Therapeutics3.7815 of 5 stars$7.18-4.9%$70.00+874.9%-24.7%$46.16M$3.27M-0.4190 Related Companies and Tools Related Companies bluebird bio Alternatives Prelude Therapeutics Alternatives Applied Therapeutics Alternatives OS Therapies Alternatives PepGen Alternatives Actinium Pharmaceuticals Alternatives Atara Biotherapeutics Alternatives Exicure Alternatives Adverum Biotechnologies Alternatives Aligos Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NERV) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
